Ameriprise Financial Inc Tricida, Inc. Transaction History

Ameriprise Financial Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $219,047 - $350,064	25,740 New	25,740 $270,000
Q4 2020 Feb 12, 2021	SELL	$4.37 - $9.46 $214,903 - $465,214	-49,177 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$8.56 - $26.93 $130,916 - $411,867	-15,294 Reduced 23.72%	49,177 $445,000
Q2 2020 Aug 14, 2020	SELL	$21.21 - $31.55 $461,911 - $687,095	-21,778 Reduced 25.25%	64,471 $1.77 Million
Q1 2020 May 15, 2020	BUY	$18.43 - $38.04 $167,196 - $345,098	9,072 Added 11.75%	86,249 $1.9 Million

Q4 2019 Feb 14, 2020	SELL	$29.6 - $43.71 $242,246 - $357,722	-8,184 Reduced 9.59%	77,177 $2.91 Million
Q3 2019 Nov 14, 2019	BUY	$29.87 - $42.22 $156,847 - $221,697	5,251 Added 6.55%	85,361 $2.64 Million
Q2 2019 Aug 14, 2019	SELL	$31.16 - $39.46 $85,876 - $108,751	-2,756 Reduced 3.33%	80,110 $3.16 Million
Q1 2019 May 15, 2019	BUY	$19.96 - $38.62 $913,329 - $1.77 Million	45,758 Added 123.31%	82,866 $3.2 Million
Q4 2018 Feb 14, 2019	BUY	$23.57 - $32.33 $874,635 - $1.2 Million	37,108 New	37,108 $875,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.